Views & Analysis | Perspectives on pharma industry issues

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

R&D

Closed & Collaborative – January to February 2026

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

Sales & Marketing

The Pandemic Treaty and the opportunity to end ‘vaccine apar...

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid.

Digital

Health Innovators – Brian Quigley and Mario Danek (Live from...

At HLTH last month, pharmaphorum Editor in Chief Jonah Comstock sat down with the CEO and CTO respectively of QNovia, Brian Quigley and Mario Danek.

Sales & Marketing

Ten ways to ‘silent-night’ in peace

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional, and global life science communications to offer some little tips for enjoying a bi

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Digital

Sponsored

STEM AI: A new lens on data-led field team performance

The relationship between pharmaceutical field teams and healthcare professionals (HCPs) is evolving rapidly.

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology